IPO fil­ings are back on the biotech menu as an AD­HD drug de­vel­op­er sub­mits its Nas­daq pa­per­work

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The sum­mer months have brought the biotech IPO mar­ket to a near stand­still af­ter a record run, but ac­tiv­i­ty is slow­ly start­ing to ramp back up again as an­oth­er com­pa­ny is tak­ing the Nas­daq plunge.

AD­HD drug de­vel­op­er Cin­gu­late filed for an IPO on Thurs­day, pen­cil­ing in a mod­est $58 mil­lion for its raise. Based out of Kansas City, KS, Cin­gu­late has a Phase III-ready AD­HD pro­gram in ad­di­tion to a fol­low-up can­di­date soon to hit the clin­ic, as well as a third pro­gram still in ear­ly pre­clin­i­cal de­vel­op­ment for anx­i­ety.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER